Notice: Trying to get property 'slug' of non-object in /home/sgumdev/public_html/wp-content/themes/sgum_2016/single.php on line 44

written by reader Confessions of a biotech fool (ATNM, MBVX, XXII)

By lumpified, October 3, 2016

That’s not fool in the motley sense, just foolish. I realise, having just become an irregular after a year or two on the sidelines, that DR KSS has described me exactly when talking about what NOT to do with small biotech stocks, i.e. buy them on the advice of exuberant newsletters without talking to anyone first!

Specifically, I hold
1. ATNM, which I now accept, after reading the long article from a year ago, is a bad idea, especially after the plunge caused by the recent issue of more stock. Advice please: get out now, or await minor plunge correction?

2. MBVX. Can’t find anything on here. Any opinions?

3. XXII. This one’s been OK, but now I read that suggestion from Dr KSS to cash in anything over 25% and see about a lower re-entry later. Again, ideas welcome!

Thanks and best wishes from Barcelona

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.



This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments
6 years ago
👍 11466
6 years ago

I’m thinking of jumping into XXII too, but haven’t taken the plunge yet.

As far as trading strategies go, they are a dime a dozen. Cashing out after a 25% rise might be a good way to go, but there are times that it is not. I have learned that the hard way. Then there are times I wish I would have done that so it’s really hard to say. There really is no right/wrong strategy. Taking profits off the table is never a bad strategy because you guarantee you profits. The only possible downside is that you risk losing future profits, but it’s never wrong to take profits.

👍 974
6 years ago
Reply to  niizajim

I’ve been in $XXI since early Sept with an AVG entry of $1.09/shr. Great article on the company in the below link. FDA news is expected any day now.


Add a Topic
👍 372

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info